Selank

Selank is a synthetic heptapeptide (sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro) derived from the human immunoglobulin G heavy chain and modified by adding three L-amino acids (Pro-Gly-Pro) at the C-terminus to enhance metabolic stability and prolong its duration of action.

Pharmacokinetics and stability highlights of Selank:

• Selank shows markedly improved metabolic stability compared to its parent fragment due to the C-terminal Pro-Gly-Pro addition, resulting in longer-lasting neuropsychotropic and anxiolytic effects.
• It demonstrates good plasma and tissue stability, with in vivo effects lasting hours to days after administration depending on dose and route.
• Selank is stable as a lyophilized powder requiring refrigeration and remains stable in sterile aqueous solutions (e.g., bacteriostatic water) for experimental use.
• It is rapidly absorbed and acts on the central nervous system, modulating neurotransmitter systems including GABAergic, dopaminergic, and serotonergic pathways.
• Selank allosterically modulates GABA-A receptors, enhancing GABA affinity, which contributes to its anxiolytic, antidepressant, and neuroprotective properties.
• It also influences gene expression related to neurotransmission and inflammation, which may underlie its multifaceted clinical effects.
Selank is extensively researched for its pronounced anxiolytic, nootropic, antistress, and immunomodulatory effects and is used for generalized anxiety disorder, cognitive enhancement, and stress relief in experimental and clinical settings.

Product details:

• Amino Acid Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP)
• Molecular Weight: Approximately 887 Da
• Purity: ≥98% (HPLC verified)
• Appearance: White to off-white lyophilized powder
• Storage: Refrigeration required to maintain stability

Selank is supplied for research use only (RUO) and is not intended for therapeutic or diagnostic use without regulatory approval.